2018 Report on

## Code of Ethics Implementation

by APEC Medical Device Industry Associations



Business Ethics for APEC SMEs Medical Device Sector

# Table of Contents


- <image>
- 1-2 INTRODUCTION
  - **3** REGIONAL OVERVIEW
  - **4** CODE GOVERNANCE
  - 5 ALIGNMENT WITH THE APEC KUALA LUMPUR PRINCIPLES
  - 6 MEMBER IMPLEMENTATION
  - **7** EXTERNAL ENGAGEMENT
- 8-9 STATISTICS BY APEC MEDICAL DEVICE INDUSTRY ASSOCIATION


## Introduction

The Business Ethics for APEC SMEs Initiative monitors code of ethics development and implementation by 34 medical device sector industry associations across the APEC region. These enterprises constitute a significant majority of the firms that develop, manufacture, market, or distribute medical device and diagnostic products in the region.

When this initiative's capacity-building program was launched in 2012 to support implementation of the APEC Kuala Lumpur Principles, 13 of these monitored medical device sector industry associations had a code of ethics. In 2018, 29 of these associations have a code of ethics or formalized commitment. The initiative remains dedicated to realizing all medical device sector industry associations that have adopted a code also achieve implementation of the code's provisions by a majority of their member enterprises. The initiative continues to pursue universal code of ethics adoption by medical device sector industry associations by 2020 with the remaining five associations without a code or code commitment located in Chile, China, Mexico, Singapore, and Chinese Taipei.

This report has been prepared for the 2018 APEC Business Ethics for SMEs Forum, to indicate where progress has been made since 2012, and where challenges remain, for the region's medical device sector industry associations in (A) code governance, (B) code alignment with the APEC Principles, (C) member enterprise implementation of the code, and (D) external stakeholder engagement on the code, a new monitoring area. The data provided in this report has been provided from the associations and other publicly available sources.







## INDUSTRY ASSOCIATIONS WITH A CODE OR CODE COMMITMENT

ASSOCIATIONS WITH A CODE OR CODE COMMITMENT ASSOCIATIONS WITHOUT A CODE OR CODE COMMITMENT


## ENTERPRISE MEMBERSHIP OF ASSOCIATIONS WHO HAVE ADOPTED A CODE OR CODE COMMITMENT



NUMBER OF MEMBER ENTERPRISES IN ASSOCIATIONS WITH A CODE



## **Regional Overview**




| Industry Associations<br>Monitored: | 34      |
|-------------------------------------|---------|
| Member Companies:                   | 13,255+ |
| SME Members Companies:              | 10,500+ |

| STATUS REPORT                                 | 2012   | 2018                   |  |  |  |
|---|--------|------------------------|--|--|--|
| Associations with a Code/<br>Code Commitment: | 13     | 29 (up 16)             |  |  |  |
| Total Member Enterprises:                     | 6,500+ | 12,700+<br>(up 6,200+) |  |  |  |
| SME Member Companies:                         | 5,700+ | 10,000+<br>(up 4,300+) |  |  |  |

## **Code Governance**


Medical device sector industry association codes of ethics are strong tools to disseminate and harmonize ethical business practices among many enterprises. However, they only serve as effective tools if robust code governance is in place. The initiative monitors several crucial areas to identify whether such governance exists. Responses from those industry associations completing the 2018 survey (19 of the 29 with codes or commitments) indicate that most continue to have a valid governance structure in place. 2018 data highlights a notable increase in associations with a staff member to oversee the code, and associations with a code complaint or violation procedure. Areas of challenge include a continued decline in resources and one-on-one assistance to members seeking to align their business practices with the code.




# **Alignment with the APEC Kuala Lumpur Principles**

The Business Ethics for APEC SMEs Initiative has conducted seven medical device sector capacity-building programs since 2012 and has extended support for dozens of local trainings to ensure that new and existing medical device industry association codes of ethics achieve alignment with the APEC Kuala Lumpur Principles and the APEC model industry association code. Among adopted codes or code commitments,

**REPORTED EMBRACE OF** THE FIVE FUNDAMENTAL **PRINCIPLES OF THE APEC KUALA LUMPUR PRINCIPLES BY THE 29 ASSOCIATIONS** WITH A CODE OR CODE **COMMITMENT:** 



**REPORTED ALIGNMENT WITH** THE PROVISIONS OF THE APEC KUALA LUMPUR PRINCIPLES BY **THE 29 ASSOCIATIONS WITH A** CODE OR CODE COMMITMENT:



many industry associations chose to incorporate the entire text of the APEC Principles while others adapted certain provisions to align with local requirements. Among the associations with a code of ethics, at least 73% report their code embraces all five fundamental principles of the


APEC Kuala Lumpur Principles and at least 55% report their code is intently aligned with all the provisions of the Principles.

## **Member Implementation**

Assessing member enterprise implementation of a medical device sector industry association's code of ethics remains the most difficult component of the initiative's monitoring activities. To-date, data is dependent on estimates provided by each association. Among the associations responding to the 2018 survey (19 of the 29 associations with codes or code commitments), 59% report their code has performed "excellent" or "well" over the past year.



| ASSOCIATION MONITORING  |     |   |
|---|-----|---|
| Associations who maintain an active list of members who have certified compliance with the code of ethics:                          | 28% |   |
| Associations who receive notification when members<br>conduct external validation or audits to measure<br>compliance with the code: | 0%  | · |





**29 ASSOCIATIONS WITH A CODE / COMMITMENT** 

9 (31%)

76-100%

**6** (22%)

26-50%

1(3%)


51-75%

## **External Engagement**

How medical device industry associations engage non-member companies, healthcare professionals, with external stakeholders (non-members) on their third party intermediaries, patient groups, codes of ethics has emerged as fourth area of governments, and other stakeholders. Among the associations responding to the 2018 survey assessment in code implementation. While important for association members to adhere (19 of the 29 associations with codes or code commitments), 47% report they have distributed and implement their code, many encounter a their code to non-member stakeholders. 79% of "non-member dilemma" of how to operate in the same market with those who do not subscribe to associations report they are interested to heighten the code of ethics. This data highlights associations external stakeholder engagement on their code who engage with external stakeholders such as of ethics.







| Association      | Economy             | Member<br>Enterpri |            |            |               |                | Member<br>Implementation |      | Participation in APEC<br>Business Ethics Forum |      |      |      |
|------------------|---------------------|--------------------|------------|------------|---------------|----------------|--------------------------|------|--|------|------|------|
|                  |                     | TOTAL              | SMEs       | Yes/<br>No | Year<br>Adopt | Last<br>Update |                          | 2014 | 2015   | 2016 | 2017 | 2018 |
| ADIA             | Australia           | 205                | 197        | Yes        | 1974          | 2017           | 76-100%                  | No   | No   | No   | No   | No   |
| ΜΤΑΑ             | Australia           | 74                 | 35         | Yes        | 2001          | 2015           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| IDV<br>Australia | Australia           | 37                 | No<br>Data | Yes        | 2010          | 2013           | No Data                  | No   | No   | No   | No   | No   |
| MEDEC            | Canada              | 78                 | 21         | Yes        | 2005          | 2017           | 26-50%                   | Yes  | Yes  | No   | Yes  | No   |
| ADIMECH          | Chile               | No<br>Data         | No<br>Data | No         | N/A           | N/A            | No Data                  | No   | No   | No   | No   | No   |
| APIS             | Chile               | 30                 | No<br>Data | Yes        | 2018          | 2018           | No Data                  | No   | No   | No   | No   | Yes  |
| SCDM             | Chile               | 27                 | 16         | Yes        | 2013          | 2018           | No Data                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| AdvaMed<br>China | China               | 40                 | 0          | Yes        | 2016          | 2017           | No Data                  | Yes  | Yes  | No   | Yes  | Yes  |
| CAMDI            | China               | 2,148              | 1,230      | Yes        | 2015          | 2016           | 26-50%                   | Yes  | Yes  | Yes  | Yes  | Yes  |
| CAME             | China               | No<br>Data         | No<br>Data | No         | N/A           | N/A            | No Data                  | No   | No   | No   | No   | No   |
| CCCMHPIE         | China               | 1,840              | 1,688      | Yes        | 2013          | 2017           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| HKMHDIA          | Hong Kong,<br>China | 178                | 150        | Yes        | 2009          | N/A            | 0-25%                    | No   | No   | No   | No   | No   |
| ΤΑΜΤΑ            | Chinese<br>Taipei   | 22                 | 0          | Yes        | 2015          | 2015           | 76-100%                  | No   | Yes  | No   | Yes  | Yes  |
| ТМВІА            | Chinese<br>Taipei   | 378                | 350        | No         | N/A           | N/A            | N/A                      | No   | No   | No   | No   | No   |
| Gakeslab         | Indonesia           | 452                | 388        | Yes        | 2013          | 2016           | 26-50%                   | Yes  | Yes  | No   | Yes  | No   |
| AMDD             | Japan               | 63                 | <10        | Yes        | 2016          | N/A            | No Data                  | No   | No   | No   | No   | Yes  |
| JFMDA            | Japan               | 4280               | 4000       | Yes        | 1993          | 2017           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| KMDIA            | Korea               | 825                | 788        | Yes        | 2011          | 2017           | No Data                  | Yes  | Yes  | Yes  | No   | Yes  |
| АММІ             | Malaysia            | 67                 | 21         | Yes        | 2013          | 2017           | No Data                  | No   | No   | No   | No   | No   |
| MMDA             | Malaysia            | 176                | 100        | Yes        | 2013          | N/A            | 26-50%                   | No   | No   | No   | No   | No   |
| AMID             | Mexico              | 32                 | 0          | Yes        | 2013          | 2017           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| ASEMED           | Mexico              | No<br>Data         | No<br>Data | No         | No<br>Data    | No<br>Data     | No Data                  | No   | No   | No   | No   | No   |

| Association      | Economy          | Member<br>Enterpr |      | Code Adoption<br>Code Commitment* |               |                | Member<br>Implementation | PEC<br>orum |      |      |      |      |
|------------------|------------------|-------------------|------|-----------------------------------|---------------|----------------|--------------------------|-------------|------|------|------|------|
|                  |                  | TOTAL             | SMEs | Yes/<br>No                        | Year<br>Adopt | Last<br>Update |                          | 2014        | 2015 | 2016 | 2017 | 2018 |
| APACMed          | Multi            | 92                | 20   | Yes                               | 2016          | 2018           | 76-100%                  | N/A         | Yes  | No   | Yes  | Yes  |
| MTANZ            | New<br>Zealand   | 105               | 52   | Yes                               | 2005          | 2016           | 26-50%                   | Yes         | No   | Yes  | Yes  | Yes  |
| COMSALUD-<br>CCL | Peru             | 188               | 138  | Yes                               | 2012          | N/A            | 26-50%                   | Yes         | Yes  | Yes  | Yes  | No   |
| MEPI             | Philippines      | 88                | 45   | Yes                               | 2015          | N/A            | N/A                      | No          | No   | No   | No   | No   |
| PAMDRAP          | Philippines      | 117               | 57   | Yes                               | 2015          | 2017           | No Data                  | Yes         | Yes  | Yes  | Yes  | Yes  |
| IMEDA            | Russia           | 48                | 0    | Yes                               | 2008          | 2013           | Unknown                  | Yes         | No   | No   | No   | No   |
| AMDI             | Singapore        | 111               | 81   | No                                | N/A           | N/A            | N/A                      | No          | No   | No   | No   | No   |
| SMF-MTIG         | Singapore        | 94                | 48   | Yes                               | 2014          | 2017           | 0-25%                    | Yes         | Yes  | No   | No   | No   |
| THAIMED          | Thailand         | 110               | 110  | Yes                               | 2008          | 2013           | 76-100%                  | Yes         | No   | No   | No   | No   |
| AdvaMed          | United<br>States | 330               | 220  | Yes                               | 1992          | 2009           | 76-100%                  | Yes         | Yes  | Yes  | Yes  | Yes  |
| MDDSC            | Viet Nam         | 20                | 0    | Yes                               | 2017          | N/A            | No Data                  | No          | No   | No   | Yes  | No   |
| VIMEDAS          | Viet Nam         | 1,000             | 750  | Yes                               | 2015          | 2016           | No Data                  | No          | No   | No   | Yes  | No   |

APEC

Asia-Pacific Economic Cooperation Business Ethics for APEC SMEs Medical Device Sector

## 2018 Report on

# Code of Ethics Implementation


by APEC Biopharmaceutical Industry Associations



**Business Ethics for APEC SMEs Biopharmaceutical Sector** 

**Economic Cooperation** 





# Table of Contents

| 1 | INTRODUCTION   |
|---|----------------|
| 2 | REGIONAL OVERV |

EW


- **3** CODE GOVERNANCE
- 4 CODE ALIGNMENT WITH THE APEC MEXICO CITY PRINCIPLES
- 5 MEMBER ENTERPRISE IMPLEMENTATION
- **6** EXTERNAL ENGAGEMENT
- 7-9 STATISTICS BY APEC BIOPHARMACEUTICAL INDUSTRY ASSOCIATION

## Introduction

The Business Ethics for APEC SMEs Initiative monitors code of ethics development and implementation by 71 biopharmaceutical sector industry associations across the APEC region. These associations collectively represent nearly 10,000 member enterprises, of which over 6,000 are identified as SMEs. These enterprises constitute a significant majority of the firms that develop, manufacture, market, or distribute pharmaceutical and/or biological products in the region.

When this initiative's capacity building program was launched in 2012 to support implementation of the APEC Mexico City Principles, 25 of these monitored biopharmaceutical sector industry associations had a code of ethics. In 2018, 55 of these associations have a code of ethics or formalized commitment. The initiative remains dedicated to realizing all biopharmaceutical sector industry associations that have adopted a code also achieve implementation of the code's






provisions by a majority of their member enterprises. The initiative also continues to pursue universal code of ethics adoption by APEC biopharmaceutical sector industry associations by 2020. The remaining 16 biopharmaceutical associations without a code or commitment are located in Chile; Hong Kong, China; Korea; Mexico; Singapore; Russia; and Chinese Taipei.

This report has been prepared for the 2018 APEC Business Ethics for SMEs Forum to indicate where progress has been made since 2012, and where challenges remain, for the region's biopharmaceutical sector industry associations in (A) code governance, (B) code alignment with the APEC Principles, (C) member enterprise implementation of the code, and (D) external stakeholder engagement on the code, a new monitoring area. The data provided in this report has been provided from the associations and other publicly available sources.



## ENTERPRISE MEMBERSHIP OF ASSOCIATIONS WHO HAVE ADOPTED A CODE OR CODE COMMITMENTS

## **Regional Overview**




| Industry Associations Monitored | l: 71  |
|---------------------------------|--------|
| Total Member Enterprises:       | 9,740+ |
| SME Members:                    | 6,390+ |

| STATUS REPORT                                 | 2012   | 2018       |
|---|--------|------------|
| Associations with a Code/<br>Code Commitment: | 25     | 55 (up 30) |
| Total Member Enterprises:                     | 3,900+ | 8,760+     |
|   |        | (up 4,860) |

## **Code Governance**

Biopharmaceutical sector industry association codes of ethics are strong tools to disseminate and harmonize ethical business practices among many enterprises. However, they only serve as effective tools if robust code governance is in place. The initiative monitors several crucial areas to identify whether such governance exists. Most key governance areas assessed in 2018 saw a similar response as 2017, with a 13% increase in associations that provide one-on-one assistance to members seeking to align their business practices with the code. There remains an opportunity for associations to expand regular code trainings, which remain low.




# Code Alignment with the APEC Mexico City Principles

The Business Ethics for APEC SMEs Initiative has conducted seven biopharmaceutical sector capacity-building programs since 2012 and has extended support for dozens of local trainings to ensure that new and existing biopharmaceutical industry association codes of ethics achieve alignment with the APEC Mexico City Principles. Among adopted codes or code commitments, many industry associations chose to incorporate the entire text of the APEC Principles while others adapted certain provisions to align with local requirements. Among the associations responding to the 2017 survey (31 of the 55 with code or commitments), **90%** report their code embraces all six fundamental principles of the APEC Mexico City Principles. A significant majority report they contain the Principles' 17 provisions (see below). The three provisions of the APEC Mexico City Principles with the lowest adherence include public sector relationships and procurement, clinical trials, and company donations for charitable purposes. These three provisions similarly had the lowest adherence rate in the 2017 survey. This report contains information based on self-reporting.

## PERCENTAGE OF ASSOCIATION CODES OF ETHICS ALIGNED WITH EACH OF THE PROVISIONS OF THE APEC MEXICO CITY PRINCIPLES (2018):


- 1. Interactions with Healthcare Professionals
- 2. Promotional Information and Activities
- 3. Safety of Medicines
- 4. Symposia and Congresses
- 5. Informational Presentations by Com. Reps 6. Entertainment
- 7. Educational Items and Gifts
- 8. Support for Continuing Medical Education
- 9. Samples
- 10. Consultant and Speaker Arrangements
- 11. Compliance Procedures and Responsibilities
- 12. Conduct and Training of Com. Reps.
- 13. Public Sector Relationships and Procuremen
- 14. Clinical Trials
- 15. Company Donations for Charitable Purposes
- 16. Patient Organizations
- 17. Adherence to Principles




## Member Enterprise Implementation

Assessing member enterprise implementation of a biopharmaceutical sector industry association's code of ethics remains the most difficult component of the initiative's monitoring activities. To-date, data is dependent on estimates provided by each association. Among the associations responding to the 2018 survey (31 of the 55 associations with codes or code commitments), **73%** report their code has performed "excellent" or "well" over the past year. Furthermore, **100%** of these associations report that a majority of their members have implemented the association's code into daily practices. In examining all 55 associations with codes or commitments, at least 69% report that a majority of their members have implemented the code. 97% of associations reported their interest in a virtual ethics compliance training and certification program and **90%** have interest to support dissemination. To support this demand, the Business Ethics for APEC SMEs Initiative will initiate a "Virtual Ethics for SMEs Compliance Program" for the biopharmaceutical sector. Testing on this program will begin in 2018.

> Associations who report requiring members to certify compliance with the code:





# **External Engagement**

How biopharmaceutical industry associations engage with external stakeholders (nonmembers) on their codes of ethics has emerged as a fourth area of assessment in code implementation. While important for association members to adhere and implement their code, many encounter a "non-member dilemma" of how to operate in the same market with those who do not subscribe to the code of ethics. This data

**COORDINATION WITH NON-MEMBER** 


AND/OR YOUR CODE OF ETHICS

STAKEHOLDERS ON ETHICAL PRACTICES

highlights associations who engage with external stakeholders on their code, such as non-member companies, healthcare professionals, third party intermediaries, patient groups, governments, and other stakeholders. Among the associations responding to the 2018 survey (31 of the 55 associations with codes or code commitments), **71%** have an interest to heighten their external engagement in the future.

ASSOCIATIONS WITH INTEREST TO HEIGHTEN EXTERNAL STAKEHOLDER ENGAGEMENT:






### ...AND FOR THE FOLLOWING PURPOSE



Your Government


Healthcare Professionals

Third Party Intermediaries



Patient Groups

**Non-member Companies** 



| Association             | Economy   | Member<br>Enterpri |            |            | Adoptie<br><i>Commi</i> t |                | Member<br>Implementation |      | cipatio<br>1ess Et |      |      |      |
|-------------------------|-----------|--------------------|------------|------------|---------------------------|----------------|--------------------------|------|--------------------|------|------|------|
|                         |           | TOTAL              | SMEs       | Yes/<br>No | Year<br>Adopt             | Last<br>Update |                          | 2014 | 2015               | 2016 | 2017 | 2018 |
| Medicines<br>Australia  | Australia | 35                 | 5          | Yes        | 1960                      | 2015           | 76-100%                  | Yes  | Yes                | No   | Yes  | Yes  |
| GBMA                    | Australia |                    | 3          | Yes        | 2010                      | 2016           | 76-100%                  | No   | No                 | No   | No   | No   |
| ІМС                     | Canada    | 50                 | 35         | Yes        | 1988                      | 2017           | 76-100%                  | Yes  | Yes                | Yes  | Yes  | Yes  |
| CGPA                    | Canada    | 9                  | 4          | Yes        | 1998                      | 2013           | No Data                  | No   | No                 | No   | No   | No   |
| ASILFA                  | Chile     | 11                 | 7          | No         | N/A                       | N/A            | N/A                      | No   | No                 | No   | No   | No   |
| CIF                     | Chile     | 22                 | 0          | Yes        | 2006                      | 2017           | 76-100%                  | No   | No                 | Yes  | Yes  | Yes  |
| CANALAB                 | Chile     | 9                  | 10         | Yes        | 2018                      | N/A            | 76-100%                  | No   | No                 | No   | No   | Yes  |
| PROLMED                 | Chile     | No<br>Data         | No<br>Data | Yes        | 2018                      | 2018           | No Data                  | No   | No                 | No   | No   | Yes  |
| СРІА                    | China     | 405                | 100        | Yes        | 2013                      | 2015           | 51-75%                   | Yes  | Yes                | No   | Yes  | Yes  |
| СССМНРІЕ                | China     | 1,840              | 1,688      | Yes        | 2013                      | 2017           | 76-100%                  | Yes  | Yes                | Yes  | Yes  | Yes  |
| PhIRDA                  | China     | 90                 | 23         | Yes        | 2015                      | N/A            | 76-100%                  | Yes  | Yes                | Yes  | No   | Yes  |
| RDPAC-CAEFI             | China     | 40                 | 0          | Yes        | 1999                      | 2017           | 76-100%                  | Yes  | Yes                | No   | Yes  | Yes  |
| САТСМ                   | China     | 700                | 500        | Yes        | 2013                      | 2015           | 76-100%                  | Yes  | No                 | No   | No   | No   |
| САРС                    | China     | 384                | 249        | Yes        | 2013                      | 2015           | 51-75%                   | Yes  | No                 | No   | No   | No   |
| All-China<br>Federation | China     | No<br>Data         | No<br>Data | Yes        | 2013                      | 2015           | No Data                  | No   | No                 | No   | No   | No   |
| СМВА                    | China     | No<br>Data         | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| СМЕА                    | China     | No<br>Data         | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| СММА                    | China     | 350                | No<br>Data | Yes        | 2013                      | 2015           | No Data                  | No   | No                 | No   | No   | No   |
| СРАРЕ                   | China     | 350                | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| СРЕМА                   | China     | No<br>Data         | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| СРЕР                    | China     | No<br>Data         | No<br>Data | Yes        | 2013                      | 2015           | No Data                  | No   | No                 | No   | No   | No   |
| СРРА                    | China     | No<br>Data         | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| СОАР                    | China     | No<br>Data         | No<br>Data | Yes        | 2015                      | N/A            | No Data                  | No   | No                 | No   | No   | No   |
| CRAECC                  | China     | No<br>Data         | No<br>Data | Yes        | 2013                      | 2015           | No Data                  | No   | No                 | No   | No   | No   |
|                         |           |                    |            |            |                           |                |                          |      |                    |      |      |      |

| Association              | Economy             | Membe<br>Enterpr |            |            | Adopti<br>Commi |                | Member<br>Implementation | Participation in APEC<br>Business Ethics Forum |      |      |      |      |
|--------------------------|---------------------|------------------|------------|------------|-----------------|----------------|--------------------------|--|------|------|------|------|
|                          |                     | TOTAL            | SMEs       | Yes/<br>No | Year<br>Adopt   | Last<br>Update |                          | 2014   | 2015 | 2016 | 2017 | 2018 |
| НКАРІ                    | Hong Kong,<br>China | 39               | 0          | Yes        | 1971            | 2017           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| НКРМА                    | Hong Kong,<br>China | 38               | 35         | No         | N/A             | N/A            | N/A                      | No   | No   | No   | No   | No   |
| PDAHK                    | Hong Kong,<br>China | 44               | 44         | No         | N/A             | N/A            | N/A                      | No   | No   | No   | No   | No   |
| GP Farmasi               | Indonesia           | 2900             | 2300       | Yes        | 2003            | 2016           | 51-75%                   | Yes  | Yes  | No   | Yes  | Yes  |
| IPMG                     | Indonesia           | 26               | 16         | Yes        | 2001            | 2017           | 76-100%                  | Yes  | Yes  | No   | Yes  | Yes  |
| JPMA                     | Japan               | 71               | 5          | Yes        | 1976            | 2017           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| JGA                      | Japan               | 43               | 25         | Yes        | 2010            | 2014           | 76-100%                  | No   | Yes  | No   | Yes  | Yes  |
| KRPIA                    | Korea               | 40               | 5          | Yes        | 2010            | N/A            | 76-100%                  | No   | No   | No   | No   | Yes  |
| КРВМА                    | Korea               | 195              | 195        | Yes        | 1994            | 2014           | 76-100%                  | Yes  | No   | No   | No   | No   |
| KoBIA                    | Korea               | 107              | 50         | No         | N/A             | N/A            | N/A                      | No   | No   | No   | No   | No   |
| ΜΟΡΙ                     | Malaysia            | 41               | 32         | Yes        | 2013            | 2016           | No Data                  | Yes  | No   | No   | No   | No   |
| PhAMA                    | Malaysia            | 45               | 2          | Yes        | 1978            | 2017           | 76-100%                  | No   | No   | No   | No   | No   |
| CANIFARMA                | Mexico              | 95               | 0          | Yes        | 2005            | 2013           | 76-100%                  | No   | No   | No   | No   | No   |
| CETIFARMA                | Mexico              | 107              | 74         | Yes        | 2005            | 2018           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| AMIIF                    | Mexico              | 43               | 30         | Yes        | 2005            | 2018           | 76-100%                  | No   | No   | No   | No   | Yes  |
| ANAFAM                   | Mexico              | 25               | 0          | Yes        | 2005            | 2013           | 51-75%                   | Yes  | Yes  | Yes  | No   | No   |
| ANADIM                   | Mexico              | No<br>Data       | No<br>Data | No         | N/A             | N/A            | No Data                  | No   | No   | No   | No   | No   |
| Medicines<br>New Zealand | New<br>Zealand      | 26               | 9          | Yes        | 1962            | 2015           | 76-100%                  | No   | No   | No   | No   | No   |
| ADIFAN                   | Peru                | 13               | 13         | Yes        | 2014            | N/A            | 76-100%                  | Yes  | Yes  | Yes  | No   | No   |
| ALAFARPE                 | Peru                | 17               | 0          | Yes        | 2016            | N/A            | 76-100%                  | No   | Yes  | Yes  | Yes  | No   |
| ALAFAL                   | Peru                | 10               | 5          | Yes        | 2016            | N/A            | 76-100%                  | No   | No   | Yes  | No   | No   |
| РСРІ                     | Philippines         | 125              | 100        | Yes        | 2014            | N/A            | 51-75%                   | Yes  | Yes  | No   | No   | No   |
| РНАР                     | Philippines         | 40               | 20         | Yes        | 1993            | 2016           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| МЕРІ                     | Philippines         | 46               | 0          | Yes        | 2015            | N/A            | No Data                  | No   | No   | No   | No   | No   |

| Association     | Economy           | Member<br>Enterprises |            |            | Adoptie<br>Commit |                | Member<br>Implementation | Participation in APEC<br>Business Ethics Forum |      |      |      |      |
|-----------------|-------------------|-----------------------|------------|------------|-------------------|----------------|--------------------------|--|------|------|------|------|
|                 |                   | TOTAL                 | SMEs       | Yes/<br>No | Year<br>Adopt     | Last<br>Update |                          | 2014   | 2015 | 2016 | 2017 | 2018 |
| AIPM            | Russia            | 44                    | 14         | Yes        | 1998              | 2016           | 76-100%                  | No   | No   | No   | No   | No   |
| ARPM            | Russia            | 20                    | 0          | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| SAPI            | Singapore         | 37                    | 0          | Yes        | <2010             | 2018           | 76-100%                  | No   | No   | No   | No   | No   |
| SMF-LSIG        | Singapore         | 48                    | 30         | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| IRPMA           | Chinese<br>Taipei | 48                    | 5          | Yes        | 1994              | 2016           | 76-100%                  | No   | No   | No   | No   | No   |
| TRPMA           | Chinese<br>Taipei | 28                    | 28         | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| ТРМА            | Chinese<br>Taipei | 210                   | 160        | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| TGPA            | Chinese<br>Taipei | 65                    | 10         | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| САРА            | Chinese<br>Taipei | 125                   | 115        | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| CPMDA           | Chinese<br>Taipei | 50                    | 16         | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| NPCA            | Chinese<br>Taipei | No<br>Data            | No<br>Data | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| TPADA           | Chinese<br>Taipei | 175                   | 165        | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| ТРММА           | Chinese<br>Taipei | 55                    | 55         | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |
| PReMA           | Thailand          | 36                    | 27         | Yes        | 1986              | 2018           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| ТРМА            | Thailand          | 67                    | 60         | Yes        | 2015              | 2018           | 0-25%                    | No   | Yes  | Yes  | Yes  | Yes  |
| GPO             | Thailand          | 1                     | 0          | Yes        | 2015              | N/A            | 76-100%                  | No   | Yes  | No   | No   | No   |
| PhRMA           | United<br>States  | 32                    | 0          | Yes        | 2002              | 2009           | 76-100%                  | Yes  | Yes  | Yes  | Yes  | Yes  |
| ААМ             | United<br>States  | 44                    | No<br>Data | Yes        | 2018              | 2018           | No Data                  | No   | No   | No   | No   | No   |
| VNPCA           | Viet Nam          | 172                   | 130        | Yes        | 2014              | 2017           | 51-75%                   | Yes  | Yes  | Yes  | Yes  | Yes  |
| Pharma<br>Group | Viet Nam          | 26                    | 0          | Yes        | 2014              | 2016           | 76-100%                  | No   | Yes  | Yes  | Yes  | Yes  |
| IQGx            | Viet Nam          | 6                     | No<br>Data | Yes        | No<br>Data        | No<br>Data     | No Data                  | No   | No   | No   | No   | No   |
| FIFARMA         | Regional          | 13                    | 0          | Yes        | 2014              | N/A            | 76-100%                  | No   | No   | Yes  | No   | No   |
| ALIFAR          | Regional          | N/A                   | N/A        | No         | N/A               | N/A            | N/A                      | No   | No   | No   | No   | No   |



Asia-Pacific Economic Cooperation Business Ethics for APEC SMEs Biopharmaceutical Sector